GT Biopharma Reports $4.5 Million Net Loss in Q2 2026, Sees Increase in Operating Expenses

GT Biopharma, Inc. has reported its financial results for the second quarter of 2026, revealing a net loss of approximately $4.5 million, a significant decrease from the $30.2 million loss recorded in the same period last year. For the first half of 2026, the company reported a net loss of $7.4 million, down from $30.9 million in the first half of 2025. The reduction in losses is attributed primarily to the absence of a prior year loss related to the initial recognition of a Greenshoe Rights liability, which amounted to $28.7 million. Despite the decrease in net losses, the company has not generated any revenue during this period.

Operating expenses for the second quarter of 2026 totaled $4.5 million, a substantial increase from $1.5 million in the same quarter of 2025. This increase was driven by a rise in research and development expenses, which reached $1.1 million compared to $363,000 in the prior year, and selling, general, and administrative expenses, which surged to $3.4 million from $1.1 million. The company noted that the increase in operating expenses was primarily due to heightened marketing efforts and legal and consulting fees.

As of June 30, 2026, GT Biopharma reported total assets of $5.8 million, a decrease from $8.1 million at the end of 2025. Current liabilities remained relatively stable at $2.2 million, down slightly from $2.3 million. The company's stockholders' equity also declined to $3.6 million from $5.8 million at the end of the previous fiscal year. The decrease in total assets and stockholders' equity reflects the ongoing operational losses and the company's reliance on financing activities to support its operations.

In terms of strategic developments, GT Biopharma continues to focus on its proprietary TriKE® and Dual Targeting TriKE® platforms, which are designed to enhance the cancer-killing abilities of natural killer cells. The company has advanced its product candidates, GTB-3650 and GTB-5550, into clinical trials, with GTB-3650 receiving FDA clearance for its IND application in June 2024 and GTB-5550 following suit in January 2026. The company is actively enrolling patients for these trials, indicating progress in its product development pipeline.

Looking ahead, GT Biopharma faces significant challenges, including the need for additional financing to sustain operations. The company has raised concerns about its ability to continue as a going concern, as it has not yet generated revenue from product sales and has sustained operating losses since inception. The management has indicated that without securing further financing, the company may need to reduce or eliminate discretionary spending, which could adversely impact its business prospects. The company is currently exploring options to regain compliance with Nasdaq's minimum bid price requirement, which is critical for maintaining its listing on the exchange.